Allscripts' (MDRX) Ready to Run Following Misys Break-Up - Cramer
Tweet
Share
E-mail
Get Alerts MDRX Hot Sheet
Join SI Premium – FREE
Shares of Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) are trading strong as Jim Cramer and CEO Glenn Tullman discussed the future of the company.
Tullman said that since their merger with Exlopsys and separation with partner Misys are complete, the company is "firing on all cylinders."
With recent federal stimulus, Tullman said that they are seeing benefit as hospitals and doctors are being payed to use Allscripts' software. He continued that some has already been earmarked for payment, and is not part of Obamacare," which is coming under fire.
Allscripts is also in tune with the changing landscape. Their software is fully compatible with Apple's iPad, as the device continues to "capture the imaginations" of physicians.
Cramer notes that shares of the stock have been depressed since the break-up with Misys, but now is the time to buy as shares are ready to run. MDRX has a growth rate of 18%, and currently trades for 12x EPS estimates.
Shares are up 1.7% in afternoon trading.
Tullman said that since their merger with Exlopsys and separation with partner Misys are complete, the company is "firing on all cylinders."
With recent federal stimulus, Tullman said that they are seeing benefit as hospitals and doctors are being payed to use Allscripts' software. He continued that some has already been earmarked for payment, and is not part of Obamacare," which is coming under fire.
Allscripts is also in tune with the changing landscape. Their software is fully compatible with Apple's iPad, as the device continues to "capture the imaginations" of physicians.
Cramer notes that shares of the stock have been depressed since the break-up with Misys, but now is the time to buy as shares are ready to run. MDRX has a growth rate of 18%, and currently trades for 12x EPS estimates.
Shares are up 1.7% in afternoon trading.
Create E-mail Alert Related Categories
Insiders' BlogRelated Entities
Jim CramerSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
